A comparison of the efficacy and safety of once-daily fluticasone furoate/vilanterol with twice-daily fluticasone propionate/salmeterol in moderate to very severe COPD

Tuesday, January 25th, 2022

This study compared the efficacy and safety of once-daily fluticasone furoate/vilanterol and twice-daily fluticasone propionate/salmeterol in 528 patients with moderate to very severe COPD. The primary endpoint was change from baseline in 0–24 hour weighted FEV1; other endpoints included time to reach a 100 mL increase in FEV1 on Day 1, change from baseline in trough FEV1 on Day 85, change in SGRQ score, and rescue-free 24-hour periods. Lung function was assessed using a Vitalograph Pneumotrac spirometer.